Oral Microbiome Therapy Tied to Low Recurrence of C. Diff

(MedPage Today) -- A potential first-in-class investigational microbiome therapeutic, SER-109, was safe and observed to sustain low Clostridioides difficile (C. diff) recurrence rates for adults, according to the phase III, single-arm ECOSPOR IV...